Loading...
•
Sep 30
Zoetis Q3 2025 Earnings Report
Zoetis reported solid financial performance in Q3 2025 with modest revenue growth and improved profitability.
Key Takeaways
Zoetis delivered $2.4 billion in revenue and $721 million in net income for Q3 2025. Adjusted EPS came in at $1.70, reflecting strong execution and growth in companion animal products and international operations.
Revenue grew to $2.4 billion, a 1% increase YoY
Adjusted EPS reached $1.70 with adjusted net income of $754 million
International revenue rose 3% while U.S. revenue declined 2%
Strong performance in parasiticides and dermatology portfolios
Zoetis
Zoetis
Zoetis Revenue by Segment
Zoetis Revenue by Geographic Location
Revenue by Segment
Companion Animal Revenue
CapyFin.comLivestock Revenue
CapyFin.comContract Mfg & Human Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Zoetis narrowed its 2025 full-year guidance slightly, expecting revenue between $9.4B and $9.475B and maintaining adjusted EPS between $6.30 and $6.40.
Positive Outlook
- Adjusted EPS maintained in the range of $6.30 to $6.40
- Organic operational growth forecast at 5.5% to 6.5%
- Strong growth expected in adjusted net income
- Innovation pipeline remains robust with new product approvals
- Disciplined execution and cost management support profitability
Challenges Ahead
- Full-year revenue guidance slightly reduced from prior forecast
- Growth moderated in Q3 as expected
- U.S. revenue declined in Q3, especially in livestock products
- Continued challenges from product divestitures
- Foreign exchange and macroeconomic conditions could remain headwinds
Revenue & Expenses
Visualization of income flow from segment revenue to net income